Skip to main content

Table 1 Baseline Characteristics of Study Subjects, including subgroups.

From: Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment

  Sex:      HIV-1 RNA  
  N Age M:F CD4+ Duration of Infectiona CDC Stage C3b ADC Stage QNPZ-4 Score Plasma CSF P-C log10 Diff. CSF WBC
   (yrs) (ratio) (cells/mm3) (mean yrs +/- SD) (percent)    (log10RNA copies/mL) (cells/mm3)
Total 100 39.0 (36.0–45.0) 91:9 181.5 (48.8 – 285.3) 9.7 (+/- 5.60) 70.3% 0 (0 – 1) -0.50 (-1.53 – 0.21) 4.73 (3.52 – 5.15) 2.74 (1.48 – 4.00) 1.30 (0.19 – 2.32) 1.0 (0.0 – 4.0)
ADC ≥ 1 = 30.0%
Subdivision by Treatment Group and Effect
Off Treatment
  46 38.0 (33.5 – 43) 42:4 195.0 (33.5 – 307.5) 7.5 (+/- 5.80) 65.2% 0 (0 – 0.5) -0.46 (-1.35 – 0.26) 4.93 (4.53 – 5.49) 3.61 (2.57 – 4.40) 1.19 (0.42 – 21.7) 2.0 (0 – 11.3)
ADC ≥ 1 = 23.1%
On Treatment (Total)
  54 43.0 (38.0-29.3) 49:5 181.5 (76.0 – 275.5) 11.09 (+/- 5.08) 75.9% 0.5 (0 – 1.0) -0.51 (-2.62 – 0.20) 3.40 (1.85 – 4.80) 1.66 (1.28 – 3.07) 1.37 (0.0 – 2.42) 1.0 (0.0 – 2.0)
ADC ≥ 1 = 36.6%
On Treatment Failures
  36 40.0 (38.0 – 47.8) 32:4 166.5 (48.3 – 276.5) 11.24 (+/- 4.18) 75.0% 0.5 (0 – 1.0) -0.42 (-2.40 – 0.25) 4.73 (3.99 – 5.04) 2.45 (1.45 – 3.64) 2.19 (1.29 – 2.59) 0.5 (0.0 – 2.8)
ADC ≥ 1 = 37.0%
  1. Values are medians with IQR in parentheses beneath, unless noted. P-Clog10 Diff. is the difference in plasma and CSF log10 HIV concentrations.
  2. aData available for 49 of the 100 subjects.
  3. bData available for 81 of the 100 subjects; categorization based on the 1993 Centers for Disease Control HIV classification system.